DeepMed Research

Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Clinical Trials

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Phase 3

Completed

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Placebo
Drug: Esketamine
Drug: Duloxetine (Oral Antidepressant)
Drug: Escitalopram (Oral antidepressant)
Drug: Sertraline (Oral Antidepressant)
Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

First Posted Date: 2015-07-10

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 719

Registration Number: NCT02493868

The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Sertraline HCl
Other: I-123-ADAM SPECT

First Posted Date: 2015-06-17

Last Posted Date: 2018-01-19

Lead Sponsor: Tri-Service General Hospital

Target Recruit Count: 37

Registration Number: NCT02473783

Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment

Phase 2

Completed

Conditions: Depression
Anxiety Disorder

Interventions: Drug: Crystalline cellulose powder
Drug: Lactobacillus Plantarum 299v
Drug: Escitalopram
Drug: Sertraline

First Posted Date: 2015-06-11

Last Posted Date: 2018-09-07

Lead Sponsor: Medical University of Bialystok

Target Recruit Count: 60

Registration Number: NCT02469545

Locations: 🇵🇱
Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland

Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin

Phase 4

Terminated

Conditions: Depression
Coronary Artery Disease

Interventions: Drug: Placebo
Drug: No treatment
Drug: Sertraline

First Posted Date: 2015-06-04

Last Posted Date: 2016-05-03

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 2

Registration Number: NCT02463110

Locations: 🇫🇷
ACTION Group - Pitié-Salpêtrière University Hospital (APHP), Paris, France

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Sertraline
Procedure: Bone Marrow Aspirate/Biopsy

First Posted Date: 2015-05-25

Last Posted Date: 2022-06-02

Lead Sponsor: Gustavo Rivero

Target Recruit Count: 14

Registration Number: NCT02452983

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Phase 3

Completed

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Placebo
Drug: Esketamine
Drug: Duloxetine (Oral Antidepressant)
Drug: Escitalopram (Oral Antidepressant)
Drug: Sertraline (Oral Antidepressant)
Drug: Venlafaxine Extended Release (XR) (New Antidepressant)

First Posted Date: 2015-04-21

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 139

Registration Number: NCT02422186

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Phase 3

Completed

Conditions: Treatment-resistant Depression

Interventions: Drug: Placebo
Drug: Esketamine
Drug: Duloxetine (Oral Antidepressant)
Drug: Escitalopram (Oral antidepressant)
Drug: Sertraline (Oral Antidepressant)
Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

First Posted Date: 2015-04-16

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 236

Registration Number: NCT02418585

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Phase 3

Completed

Conditions: Treatment-resistant Depression

Interventions: Drug: Placebo
Drug: Esketamine
Drug: Duloxetine (Oral Antidepressant)
Drug: Escitalopram (Oral antidepressant)
Drug: Sertraline (Oral Antidepressant)
Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

First Posted Date: 2015-04-15

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 346

Registration Number: NCT02417064

A Trial of Sertraline in Young Children With Autism Spectrum Disorder

Phase 2

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Sertraline Liquid Placebo
Drug: Sertraline

First Posted Date: 2015-03-11

Last Posted Date: 2019-10-22

Lead Sponsor: Randi J. Hagerman, MD

Target Recruit Count: 58

Registration Number: NCT02385799

Locations: 🇺🇸
UC Davis MIND Institute, Sacramento, California, United States

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy